This study aims to estimate the cost-effectiveness of first-line COMT inhibition with opicapone versus entacapone in people with PD taking levodopa and experiencing end-of-dose motor fluctuations from the perspective of the English National Health Service (NHS) and personal social services (PSS). Here, COMT is linked to Parkinson disease.